Delcath Systems (DCTH)
Commercializing HEPZATO in the United States and CHEMOSAT in Europe for liver-directed oncology.
$16.45
After-hours close+0.07 (+0.43%)
At close$16.38(+1.68%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 3 | 8 | 11 | 15 | 20 | 24 | 21 | 21 | 25 | 29 |
| Cost of revenue | 0 | 0 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 3 |
| Gross profit | 0 | 0 | 2 | 6 | 10 | 13 | 17 | 21 | 18 | 18 | 21 | 26 |
| 11 | 12 | 13 | 10 | 11 | 10 | 16 | 18 | 18 | 20 | 23 | 24 | |
| Research & development | 5 | 5 | 4 | 3 | 4 | 3 | 5 | 7 | 8 | 9 | 10 | 10 |
| 6 | 7 | 9 | 7 | 7 | 7 | 11 | 11 | 10 | 11 | 13 | 13 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
| Operating income | −11 | −11 | −10 | −4 | −1 | 3 | 1 | 3 | 0 | −2 | −2 | 2 |
| −10 | 0 | −1 | −10 | 3 | −6 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 9 | 0 | 1 | 10 | −3 | −7 | −1 | −1 | −1 | −1 | −1 | −1 |
| Income before tax | −20 | −11 | −11 | −14 | 2 | −3 | 1 | 3 | 0 | −1 | −1 | 3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Net income from continuing operations | −20 | −11 | −11 | −14 | 2 | −3 | 1 | 3 | 1 | −2 | −1 | 3 |
| Net income | −20 | −11 | −11 | −14 | 2 | −3 | 1 | 3 | 1 | −2 | −1 | 3 |
| EPS, basic | −$1.14 | −$0.49 | −$0.45 | −$0.48 | $0.07 | −$0.12 | $0.03 | $0.08 | $0.02 | −$0.05 | −$0.03 | $0.07 |
| EPS, diluted | −$1.14 | −$0.49 | −$0.45 | −$0.48 | $0.06 | −$0.12 | $0.03 | $0.07 | $0.02 | −$0.05 | −$0.03 | $0.07 |
| Weighted average shares, basic | 18 | 23 | 25 | 28 | 29 | 28 | 35 | 36 | 36 | 36 | 36 | 36 |
| Weighted average shares, diluted | 18 | 23 | 25 | 28 | 32 | 28 | 40 | 40 | 40 | 40 | 36 | 40 |
| EBITDA | −20 | −11 | −11 | −14 | 2 | 10 | 1 | 3 | 0 | −1 | −1 | 3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −20 | −11 | −11 | −14 | 2 | 10 | 1 | 3 | 0 | −1 | −1 | 3 |